Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 4/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19063652 | 1.00 | BCHE (0.46) | BCHETDP1ATMNT5EKMT2A | |
| SCHEMBL20549100 | 1.00 | BCHE (0.46) | BCHETDP1ATMNT5EKMT2A | |
| SCHEMBL19063874 | 0.87 | BCHE (0.45) | BCHETDP1ATMNT5EKMT2A | |
| SCHEMBL19063875 | 0.87 | BCHE (0.45) | BCHETDP1ATMNT5EKMT2A | |
| SCHEMBL20549043 | 0.87 | BCHE (0.45) | BCHETDP1ATMNT5EKMT2A | |
| SCHEMBL2348366 | 0.84 | BCHE (0.44) | BCHETDP1ATMNT5EKMT2A | |
| SCHEMBL2348371 | 0.84 | BCHE (0.44) | BCHETDP1ATMNT5EKMT2A | |
| SCHEMBL19098658 | 0.84 | ALDH1A1 (0.47) | BCHEKMT2AALDH1A1MAPTLMNA | |
| SCHEMBL31566991 | 0.82 | ABCB1 (0.46) | KMT2APKMMAPTABCB1NPC1 | |
| SCHEMBL13382281 | 0.82 | ABCB1 (0.46) | KMT2APKMMAPTABCB1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562909-B2 | Fused quadracyclic compounds, compositions and uses thereof | Tabomedex Biosciences, LLC (US) | 2020-02-18 | — | — | US | disclosed |
| US-20180319809-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Tabomedex Biosciences, LLC | 2018-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319809-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | MKNK2, CYP2J2, PTGS2 | BCHE 4165/4885TDP1 4112/4885ATM 3068/4885 |
| US-10562909-B2 | Fused quadracyclic compounds, compositions and uses thereof | MKNK2, CYP2J2, PTGS2 | BCHE 4165/4885TDP1 4112/4885ATM 3068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.